Skip to content
zameds

Fludarabine (Fludarabine Teva)

Fludarabine

Teva Pharmaceuticals (Pty) Ltd

S4

Registration

Applicant
Teva Pharmaceuticals (Pty) Ltd
Certificate holder
Teva Pharmaceuticals (Pty) Ltd.
Registrations
1
Schedule source
Consolidated Schedules 06 July 2026

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Fludarabine 50 teva

EACH 2,0 ml VIAL CONTAINS FLUDARABINE PHOSPHATE 50,0 mg

2 mlConcentrate for solution for injection or infusion43000943/26/0009Approved 29 April 2026RegisteredS4PIPIL

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Fludarabine phosphate

  • S4: Fludarabine

    Consolidated Schedules 06 July 2026, line 6359

Pharmacological class: Cytostatic agents (class 26)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C10H13FN5O7P365.21 g/mol

[(2R,3S,4S,5R)-5-(6-Amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

Drag to rotate. Structure from PubChem CID 30751.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles